DIABNEXT s’est fait avaler par l’Américain Glooko, spécialisé lui aussi dans la télésurveillance des personnes atteintes de diabète. Il souhaite avec ce rachat conquérir de nouveaux patients en France.

Glooko is the latest newsmaker for diabetes tech – as the company is quickly hopping back on the M&A trail after the xBird deal in February. Glooko has acquired DIABNEXT, a company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers.

Digital diabetes management company Glooko has acquired Paris-based DIABNEXT, a fellow diabetes care platform.

Glooko announced that it acquired DIABNEXT, a developer of a digital health platform for managing diabetes and connecting to healthcare providers.

Das Berliner Digital-Health-Unternehmen xbird wird von der auf Diabetes-Telemonitoring spezialisierten Glooko aus den USA übernommen.

Glooko acquires xbird, a company developing AI-driven just in time adaptive interventions.

Digital health company Glooko acquired xbird, a medical AI company with Just In Time Adaptive Intervention technologies to predict patient behavior and offer behavioral changes accordingly to improve outcomes for patients with diabetes.

Glooko, Inc., ein führender Anbieter von Datenmanagement- und Telemonitoringlösungen für Diabetes und andere chronische Erkrankungen, gab heute die Akquisition des Berliner Digital Health Unternehmens xbird bekannt.

Glooko has made a name for itself in digital health circles with its data management tools for diabetes patients and has now added artificial intelligence capabilities with its acquisition of xbird.

Transaktion erweitert Glookos Expertise um Machine Learning und Just-In-Time Adaptive Intervention (JITAI) Technologien